The guanylate cyclase C agonist, linaclotide (Linzess), doubled weekly bowel movements among children age 6 and younger, helping to treat pediatric patients with functional constipation, according to a study published in Lancet Gastroenterology & Hepatology. As a recently approved treatment option, linaclotide demonstrated improvement in frequency over placebo with 57% of patients in the treatment group experiencing a spontaneous bowel movement within the first 48 hours of receiving the drug. Authors also observed improvement in …
Read More